Search
Vorasidenib
go.drugbank.com/drugs/DB17097ApprovedInvestigationalVorasidenib is a first-in-class dual isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor. … [A264209] It works by suppressing the levels of D-2-hydroxyglutarate (2-HG), an oncometabolite produced by mutant IDH1 and IDH2 isoforms.
Ferric derisomaltose
go.drugbank.com/drugs/DB15617ApprovedInvestigationalThe latter is an iron carbohydrate oligosaccharide that works to release iron. Ferric derisomaltose was developed by Pharmacosmos Therapeutics ad was granted FDA approval in January 2020. … Iron deficiency is an extremely common condition and is the most frequent cause of anemia worldwide.
Products: Monofer 100 mg/ml solution for injection/infusion in vials, Monofer 100mg/ml solution for injection/infusion in ampoulesHydroxyproline
go.drugbank.com/drugs/DB08847ApprovedTherapeutically, hydroxyproline is being studied as an an experimental medicine but is approved in France as a combination topical gel product called Cicactive for small, superficial wounds. … It is found in collagen and as such it is common in many gelatin products. Hydroxyproline is mostly used as a diagnostic marker of bone turnover and liver fibrosis.
Pralatrexate
go.drugbank.com/drugs/DB06813ApprovedInvestigational[A246703] Pralatrexate was approved by the FDA on September 24, 2009. … [A246693] Compared to methotrexate, pralatrexate has better accumulation in cancer cells.
Synonyms: N-(4-(1-((2,4-Diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-L-glutamic acid, (2S)-2-({4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}amino)pentanedioic acidImipenem
go.drugbank.com/drugs/DB01598ApprovedInvestigational[A15389] Imipenem is commonly used in combination with [cilastatin] and is now available in a triple-drug product with cilastatin and [relebactam] which was recently approved by the FDA. … Imipenem was first approved by the FDA in November 1985 as the combination product Primaxin marketed by Merck & Co.[L7628]
Synonyms: N-formimidoylthienamycin, N-formimidoyl thienamycinMixtures: IMIPENEM E CILASTATINA SUN, IMIPENEM E CILASTATINA SUNLevomilnacipran
go.drugbank.com/drugs/DB08918ApprovedInvestigational[L47946] First approved by the FDA on July 25, 2013, levomilnacipran is used to treat major depressive disorder in adults. … [A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].
Synonyms: CYCLOPROPANECARBOXAMIDE, 2-(AMINOMETHYL)-N,N-DIETHYL-1-PHENYL-, (1S,2R)-Magnesium Aluminum Silicate
go.drugbank.com/drugs/DB11230ApprovedWithdrawnIt is refined to a powder for use in cosmetic and pharmaceutical applications as an absorbent, anticaking agent, opacifying agent, viscosity-increasing agent, suspending agent, tablet and capsule disintegrant
Iloperidone
go.drugbank.com/drugs/DB04946ApprovedInvestigationalIloperidone is a benzisoxazole [A263557] and an atypical antipsychotic agent that was first approved by the FDA on May 6, 2009.
Dorocubicel
go.drugbank.com/drugs/DB19448Approved[L54106] Dorocubicel, as a component of Zemcelpro, was granted conditional marketing authorization in the European Union in August 2025 for use in allogeneic hematopoietic stem cell transplantation … following myeloablative conditioning in adult patients for whom a suitable donor is not available.
Desmopressin
go.drugbank.com/drugs/DB00035ApprovedInvestigationalDesmopressin is primarily indicated for the treatment of central diabetes insipidus, primary nocturnal enuresis (bedwetting) in children, and nocturia in adults [A275458, L56104]. … On January 15, 2026, the FDA approved a new low-dose sublingual film formulation specifically for the treatment of nocturia in patients at high risk for fluid overload, utilizing a specialized delivery